Greenwich LifeSciences Reports Q1 2025 Losses and Zero Revenue Amidst Ongoing Funding Challenges

Greenwich LifeSciences, Inc. (NASDAQ: GLSI) recently filed its quarterly report for the period ending March 31, 2025. The report highlights significant financial metrics along with insights into the company's performance and outlook.

Key Highlights:

• Revenue: The company reported $0 in revenue for both Q1 2025 and Q1 2024.
• Net Loss: Net loss for Q1 2025 was $3,258,362, compared to a loss of $2,473,195 in Q1 2024.
• Earnings Per Share: Loss per common share was $0.25 for Q1 2025 versus $0.19 in Q1 2024.
• Operating Expenses: Total operating expenses rose by 29% to $3,282,332, driven by increased research and development expenses ($2,601,122) and general and administrative expenses ($681,210).
• Cash Position: The company reported cash reserves of $2,749,959 as of March 31, 2025, down from $4,091,990 at the end of the previous quarter.
• Equity Financing: During Q1 2025, Greenwich LifeSciences raised $492,423 through an At The Market (ATM) offering, selling 39,918 shares at an average price of $12.52 per share.

Positive Aspects:

• Successful equity financing through ATM offerings, providing additional liquidity.
• Company remains focused on developing its breast cancer immunotherapy, with plans to expand clinical trials to Europe.

Negative Aspects:

• Continued absence of revenue, which raises concerns about sustainability.
• Significant net losses compared to the previous year, reflecting increasing operational expenses and a lack of revenue generation.
• Going concern doubts noted in the report, indicating potential challenges in continuing operations without additional capital.

Overall, Greenwich LifeSciences, Inc. is navigating through a critical phase as it develops its clinical pipeline to address breast cancer while seeking additional funding to stabilize its operations. Investors are advised to monitor the company's progress, especially in upcoming clinical trials and future fundraising efforts.